Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis

Nicolas Jacquelot, María Paula Roberti, David P. Enot, Sylvie Rusakiewicz, Michaela Semeraro, Sarah Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Christophe Borg, Benjamin Weide, François Aubin, Stéphane Dalle, Holbrook Kohrt, Maha Ayyoub, Guido Kroemer, Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont, Laurence Zitvogel

Research output: Contribution to journalArticle

Abstract

Stage III metastatic melanomas require adequate adjuvant immunotherapy to prevent relapses. Prognostic factors are awaited to optimize the clinical management of these patients. The magnitude of metastatic lymph node invasion and the BRAFV600 activating mutation have clinical significance. Based on a comprehensive immunophenotyping of 252 parameters per patient in paired blood and metastatic lymph nodes performed in 39 metastatic melanomas, we found that blood markers were as contributive as tumor-infiltrated lymphocyte immunotypes, and parameters associated with lymphocyte exhaustion/suppression showed higher clinical significance than those related to activation or lineage. High frequencies of CD45RA+CD4+ and CD3CD56 tumor-infiltrated lymphocytes appear to be independent prognostic factors of short progression-free survival. High NKG2D expression on CD8+tumor-infiltrated lymphocytes, low level of regulatory T-cell tumor-infiltrated lymphocytes, and low PD-L1 expression on circulating T cells were retained in the multivariate Cox analysis model to predict prolonged overall survival. Prospective studies are needed to determine whether such immunological markers may guide adjuvant therapies in stage III metastatic melanomas.

Original languageEnglish (US)
Pages (from-to)994-1001
Number of pages8
JournalJournal of Investigative Dermatology
Volume136
Issue number5
DOIs
StatePublished - 2016
Externally publishedYes

Fingerprint

Immunophenotyping
Lymphocytes
Melanoma
Tumors
T-cells
Neoplasms
Blood
Lymph Nodes
Regulatory T-Lymphocytes
Proportional Hazards Models
Immunotherapy
Disease-Free Survival
Multivariate Analysis
Chemical activation
Prospective Studies
T-Lymphocytes
Recurrence
Mutation
Survival

ASJC Scopus subject areas

  • Dermatology
  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Semeraro, M., Jégou, S., ... Zitvogel, L. (2016). Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. Journal of Investigative Dermatology, 136(5), 994-1001. https://doi.org/10.1016/j.jid.2015.12.042

Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. / Jacquelot, Nicolas; Roberti, María Paula; Enot, David P.; Rusakiewicz, Sylvie; Semeraro, Michaela; Jégou, Sarah; Flores, Camila; Chen, Lieping; Kwon, Byoung S.; Borg, Christophe; Weide, Benjamin; Aubin, François; Dalle, Stéphane; Kohrt, Holbrook; Ayyoub, Maha; Kroemer, Guido; Marabelle, Aurélien; Cavalcanti, Andréa; Eggermont, Alexander; Zitvogel, Laurence.

In: Journal of Investigative Dermatology, Vol. 136, No. 5, 2016, p. 994-1001.

Research output: Contribution to journalArticle

Jacquelot, N, Roberti, MP, Enot, DP, Rusakiewicz, S, Semeraro, M, Jégou, S, Flores, C, Chen, L, Kwon, BS, Borg, C, Weide, B, Aubin, F, Dalle, S, Kohrt, H, Ayyoub, M, Kroemer, G, Marabelle, A, Cavalcanti, A, Eggermont, A & Zitvogel, L 2016, 'Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis', Journal of Investigative Dermatology, vol. 136, no. 5, pp. 994-1001. https://doi.org/10.1016/j.jid.2015.12.042
Jacquelot, Nicolas ; Roberti, María Paula ; Enot, David P. ; Rusakiewicz, Sylvie ; Semeraro, Michaela ; Jégou, Sarah ; Flores, Camila ; Chen, Lieping ; Kwon, Byoung S. ; Borg, Christophe ; Weide, Benjamin ; Aubin, François ; Dalle, Stéphane ; Kohrt, Holbrook ; Ayyoub, Maha ; Kroemer, Guido ; Marabelle, Aurélien ; Cavalcanti, Andréa ; Eggermont, Alexander ; Zitvogel, Laurence. / Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. In: Journal of Investigative Dermatology. 2016 ; Vol. 136, No. 5. pp. 994-1001.
@article{6c24e9ddfcf54efeb8a7f14466b57b92,
title = "Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis",
abstract = "Stage III metastatic melanomas require adequate adjuvant immunotherapy to prevent relapses. Prognostic factors are awaited to optimize the clinical management of these patients. The magnitude of metastatic lymph node invasion and the BRAFV600 activating mutation have clinical significance. Based on a comprehensive immunophenotyping of 252 parameters per patient in paired blood and metastatic lymph nodes performed in 39 metastatic melanomas, we found that blood markers were as contributive as tumor-infiltrated lymphocyte immunotypes, and parameters associated with lymphocyte exhaustion/suppression showed higher clinical significance than those related to activation or lineage. High frequencies of CD45RA+CD4+ and CD3–CD56– tumor-infiltrated lymphocytes appear to be independent prognostic factors of short progression-free survival. High NKG2D expression on CD8+tumor-infiltrated lymphocytes, low level of regulatory T-cell tumor-infiltrated lymphocytes, and low PD-L1 expression on circulating T cells were retained in the multivariate Cox analysis model to predict prolonged overall survival. Prospective studies are needed to determine whether such immunological markers may guide adjuvant therapies in stage III metastatic melanomas.",
author = "Nicolas Jacquelot and Roberti, {Mar{\'i}a Paula} and Enot, {David P.} and Sylvie Rusakiewicz and Michaela Semeraro and Sarah J{\'e}gou and Camila Flores and Lieping Chen and Kwon, {Byoung S.} and Christophe Borg and Benjamin Weide and Fran{\cc}ois Aubin and St{\'e}phane Dalle and Holbrook Kohrt and Maha Ayyoub and Guido Kroemer and Aur{\'e}lien Marabelle and Andr{\'e}a Cavalcanti and Alexander Eggermont and Laurence Zitvogel",
year = "2016",
doi = "10.1016/j.jid.2015.12.042",
language = "English (US)",
volume = "136",
pages = "994--1001",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis

AU - Jacquelot, Nicolas

AU - Roberti, María Paula

AU - Enot, David P.

AU - Rusakiewicz, Sylvie

AU - Semeraro, Michaela

AU - Jégou, Sarah

AU - Flores, Camila

AU - Chen, Lieping

AU - Kwon, Byoung S.

AU - Borg, Christophe

AU - Weide, Benjamin

AU - Aubin, François

AU - Dalle, Stéphane

AU - Kohrt, Holbrook

AU - Ayyoub, Maha

AU - Kroemer, Guido

AU - Marabelle, Aurélien

AU - Cavalcanti, Andréa

AU - Eggermont, Alexander

AU - Zitvogel, Laurence

PY - 2016

Y1 - 2016

N2 - Stage III metastatic melanomas require adequate adjuvant immunotherapy to prevent relapses. Prognostic factors are awaited to optimize the clinical management of these patients. The magnitude of metastatic lymph node invasion and the BRAFV600 activating mutation have clinical significance. Based on a comprehensive immunophenotyping of 252 parameters per patient in paired blood and metastatic lymph nodes performed in 39 metastatic melanomas, we found that blood markers were as contributive as tumor-infiltrated lymphocyte immunotypes, and parameters associated with lymphocyte exhaustion/suppression showed higher clinical significance than those related to activation or lineage. High frequencies of CD45RA+CD4+ and CD3–CD56– tumor-infiltrated lymphocytes appear to be independent prognostic factors of short progression-free survival. High NKG2D expression on CD8+tumor-infiltrated lymphocytes, low level of regulatory T-cell tumor-infiltrated lymphocytes, and low PD-L1 expression on circulating T cells were retained in the multivariate Cox analysis model to predict prolonged overall survival. Prospective studies are needed to determine whether such immunological markers may guide adjuvant therapies in stage III metastatic melanomas.

AB - Stage III metastatic melanomas require adequate adjuvant immunotherapy to prevent relapses. Prognostic factors are awaited to optimize the clinical management of these patients. The magnitude of metastatic lymph node invasion and the BRAFV600 activating mutation have clinical significance. Based on a comprehensive immunophenotyping of 252 parameters per patient in paired blood and metastatic lymph nodes performed in 39 metastatic melanomas, we found that blood markers were as contributive as tumor-infiltrated lymphocyte immunotypes, and parameters associated with lymphocyte exhaustion/suppression showed higher clinical significance than those related to activation or lineage. High frequencies of CD45RA+CD4+ and CD3–CD56– tumor-infiltrated lymphocytes appear to be independent prognostic factors of short progression-free survival. High NKG2D expression on CD8+tumor-infiltrated lymphocytes, low level of regulatory T-cell tumor-infiltrated lymphocytes, and low PD-L1 expression on circulating T cells were retained in the multivariate Cox analysis model to predict prolonged overall survival. Prospective studies are needed to determine whether such immunological markers may guide adjuvant therapies in stage III metastatic melanomas.

UR - http://www.scopus.com/inward/record.url?scp=84978144220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978144220&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2015.12.042

DO - 10.1016/j.jid.2015.12.042

M3 - Article

C2 - 26829031

AN - SCOPUS:84978144220

VL - 136

SP - 994

EP - 1001

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 5

ER -